Immunicum AB (1YG0) AI Stock Analysis

Immunicum AB

(Frankfurt:1YG0)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low leverageVery low leverage gives Immunicum greater financial flexibility than many early-stage biotech companies. Limited debt reduces interest and refinancing pressure, allowing more of its available capital to support clinical development and other strategic priorities.

Negative Factors

No recurring revenue baseZero revenue across the latest TTM and two annual periods leaves the company without a consistent commercial funding base. Operations therefore remain dependent on external financing or collaboration-related payments rather than repeatable product sales.

Immunicum AB (1YG0) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 31.69M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -3.1
Beta (1Y): 0.30
Revenue Growth: ―
EPS Growth: 13.10%
Country: Germany
Employees: 19
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Immunicum AB Business Overview & Revenue Model

Company Description

Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound,...

Immunicum AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:1YG0 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CANTA	70Outperform	SEK 451.68M	2.35	63.09%	―	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ELIC	48Neutral	SEK 177.19M	-7.51	-56.09%	―	―	14.10%
SE:ONCO	47Neutral	SEK 721.66M	-2.14	―	―	87.23%	35.27%
SE:BINV	43Neutral	SEK 357.32M	-0.73	-128.54%	―	-83.67%	-50.29%
SE:ATORX	38Underperform	SEK 35.32M	-0.01	-439.98%	―	-99.33%	64.90%

* Healthcare Sector Average

Performance Comparison

DE:1YG0 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:1YG0	Immunicum AB	0.48	-0.19	-28.10%
SE:ATORX	Alligator Bioscience AB	0.01	-0.38	-97.42%
SE:BINV	BioInvent International AB	5.43	-28.47	-83.98%
SE:ONCO	Oncopeptides AB	1.67	-3.75	-69.16%
SE:ELIC	Elicera Therapeutics AB	2.65	-3.44	-56.47%
SE:CANTA	Cantargia AB	1.60	-1.97	-55.13%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Immunicum AB AI Stock Analysis